An interventional study of 100% pomegranate juice and placebo beverage in Crohn's Disease and Ulcerative Colitis, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Basic science
The aim of this research is to study the effects of a pomegranate juice on calprotectin levels in patients suffering of inflammatory bowel disease (IBD) in clinical remission. Fecal calprotectin levels, surrogate marker of mucosal inflammation, will be measured from baseline to 12 weeks later (end of intervention). Systemic and mucosal changes of biochemical and molecular inflammatory response markers will be also assessed.
The main purpose of the intervention trial is to assess the possible effect of pomegranate juice consumption on reducing fecal calprotectin (FC) levels in volunteers suffering from IBD with a high risk of clinical relapse. In detail, the objectives of this intervention are as follows: (i) assessing the changes in FC levels in the two groups (active treatment, control) from baseline to 12 weeks later (primary outcome); (ii) investigating the systemic and mucosal modifications of selected biochemical and molecular inflammatory response markers in the two groups after 12 weeks of the intervention compared with baseline (secondary outcomes); (iii) evaluating circulating and urinary ellagitannin-derived metabolites from regular pomegranate juice consumption in the two groups before and after the intervention.
The detailed study protocol is published in the Trials journal.
Exclusion Criteria:
The pomegranate juice is 100% pomegranate juice, not from concentrate.
Other: 100% pomegranate juice
The placebo beverage consists in water added with sugar and citric acid.
Other: placebo beverage
125 mL of 100% pomegranate juice twice daily for 12 weeks
125 mL of placebo beverage twice daily for 12 weeks
Changes in fecal calprotectin
Change from baseline in fecal neutrophil-derived protein calprotectin, surrogate marker of mucosal improvement, after 12 weeks of consumption of experimental or placebo beverage, in subjects affected by IBD in clinical remission.
Time frame: Baseline and 12 weeks
Changes in plasma concentration of ellagitannin metabolites
Change from baseline in plasma concentration of ellagitannin metabolites after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Changes in circulating cytokines levels
Change from baseline in plasma levels of cytokines after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Changes in circulating trimethylamine-N-oxide (TMAO) levels
Change from baseline in plasma levels of TMAO after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Changes in gene expression levels in peripheral blood mononuclear cells (PBMC)
Change from baseline in expression levels of selected genes in PBMC by qPCR after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Changes in gene expression levels in intestinal biopsies
Change from baseline in expression levels of selected genes in intestinal biopsies by qPCR after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Changes in urinary ellagitannin metabolite excretion
Change from baseline in urinary ellagitannin metabolite excretion after 12 weeks of intervention.
Time frame: Baseline and 12 weeks
Plan to share: No
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna